Historical Valuation
Avadel Pharmaceuticals PLC (AVDL) is now in the Undervalued zone, suggesting that its current forward PS ratio of 6.14 is considered Undervalued compared with the five-year average of 127.27. The fair price of Avadel Pharmaceuticals PLC (AVDL) is between 175.09 to 183.87 according to relative valuation methord. Compared to the current price of 21.50 USD , Avadel Pharmaceuticals PLC is Undervalued By 87.72%.
Relative Value
Fair Zone
175.09-183.87
Current Price：21.50
87.72%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Avadel Pharmaceuticals PLC (AVDL) has a current Price-to-Book (P/B) ratio of 21.30. Compared to its 3-year average P/B ratio of 16.09 , the current P/B ratio is approximately 32.41% higher. Relative to its 5-year average P/B ratio of 16.09, the current P/B ratio is about 32.41% higher. Avadel Pharmaceuticals PLC (AVDL) has a Forward Free Cash Flow (FCF) yield of approximately 1.63%. Compared to its 3-year average FCF yield of -4.82%, the current FCF yield is approximately -133.71% lower. Relative to its 5-year average FCF yield of -4.82% , the current FCF yield is about -133.71% lower.
P/B
Median3y
16.09
Median5y
16.09
FCF Yield
Median3y
-4.82
Median5y
-4.82
Competitors Valuation Multiple
AI Analysis for AVDL
The average P/S ratio for AVDL competitors is 205.90, providing a benchmark for relative valuation. Avadel Pharmaceuticals PLC Corp (AVDL.O) exhibits a P/S ratio of 6.14, which is -97.02% above the industry average. Given its robust revenue growth of 54.86%, this premium appears sustainable.
Performance Decomposition
AI Analysis for AVDL
1Y
3Y
5Y
Market capitalization of AVDL increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of AVDL in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is AVDL currently overvalued or undervalued?
Avadel Pharmaceuticals PLC (AVDL) is now in the Undervalued zone, suggesting that its current forward PS ratio of 6.14 is considered Undervalued compared with the five-year average of 127.27. The fair price of Avadel Pharmaceuticals PLC (AVDL) is between 175.09 to 183.87 according to relative valuation methord. Compared to the current price of 21.50 USD , Avadel Pharmaceuticals PLC is Undervalued By 87.72% .
What is Avadel Pharmaceuticals PLC (AVDL) fair value?
AVDL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Avadel Pharmaceuticals PLC (AVDL) is between 175.09 to 183.87 according to relative valuation methord.
How does AVDL's valuation metrics compare to the industry average?
The average P/S ratio for AVDL's competitors is 205.90, providing a benchmark for relative valuation. Avadel Pharmaceuticals PLC Corp (AVDL) exhibits a P/S ratio of 6.14, which is -97.02% above the industry average. Given its robust revenue growth of 54.86%, this premium appears sustainable.
What is the current P/B ratio for Avadel Pharmaceuticals PLC (AVDL) as of Jan 10 2026?
As of Jan 10 2026, Avadel Pharmaceuticals PLC (AVDL) has a P/B ratio of 21.30. This indicates that the market values AVDL at 21.30 times its book value.
What is the current FCF Yield for Avadel Pharmaceuticals PLC (AVDL) as of Jan 10 2026?
As of Jan 10 2026, Avadel Pharmaceuticals PLC (AVDL) has a FCF Yield of 1.63%. This means that for every dollar of Avadel Pharmaceuticals PLC’s market capitalization, the company generates 1.63 cents in free cash flow.
What is the current Forward P/E ratio for Avadel Pharmaceuticals PLC (AVDL) as of Jan 10 2026?
As of Jan 10 2026, Avadel Pharmaceuticals PLC (AVDL) has a Forward P/E ratio of 31.13. This means the market is willing to pay $31.13 for every dollar of Avadel Pharmaceuticals PLC’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Avadel Pharmaceuticals PLC (AVDL) as of Jan 10 2026?
As of Jan 10 2026, Avadel Pharmaceuticals PLC (AVDL) has a Forward P/S ratio of 6.14. This means the market is valuing AVDL at $6.14 for every dollar of expected revenue over the next 12 months.